Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Receivables (2016 - 2026)

Tandem Diabetes Care filings provide 13 years of Receivables readings, the most recent being $173.9 million for Q4 2025.

  • On a quarterly basis, Receivables rose 51.75% to $173.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $173.9 million, a 51.75% increase, with the full-year FY2025 number at $173.9 million, up 51.75% from a year prior.
  • Receivables hit $173.9 million in Q4 2025 for Tandem Diabetes Care, up from $125.9 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $173.9 million in Q4 2025 to a low of $77.2 million in Q1 2021.
  • Median Receivables over the past 5 years was $105.5 million (2022), compared with a mean of $107.7 million.
  • Biggest five-year swings in Receivables: surged 67.86% in 2021 and later dropped 11.07% in 2023.
  • Tandem Diabetes Care's Receivables stood at $110.7 million in 2021, then grew by 7.51% to $119.0 million in 2022, then fell by 7.22% to $110.5 million in 2023, then grew by 3.74% to $114.6 million in 2024, then surged by 51.75% to $173.9 million in 2025.
  • The last three reported values for Receivables were $173.9 million (Q4 2025), $125.9 million (Q3 2025), and $128.4 million (Q2 2025) per Business Quant data.